GermanyGermany

Germany launches EUR200 million biotechnology research programme

12.07.2010

Berlin – Germany is to invest EUR200 million over the coming 15 years to develop the next generation of biotechnology processes. “The full potential of biotechnology isn’t yet fully exploited”, said BMBF State Secretary Helge Braun during the presentation of the new Biotechnology 2020 Plus programme in Berlin. “We can change this by applying engineering principles to biotechnology.” A long-term goal of the ambitious programme is to separate biological functions from cells, and to create robust reaction modules that can mimic biological processes even under harsh reaction conditions. This would enable engineers to integrate the water-soluble biological processes into existing industrial value chains, for example using cell-free photosynthesis modules for energy production, or artificial enzymes or cell modules to produce chemicals in a solvent-free environment. Because most of these goals are currently more vision than reality, the Ministry for Research has kicked off a so-called strategy process that brings together experts from a variety of fields to discuss the kinds of projects required to realise the biologisation of industrial processes. Four major research organisations have signed a memorandum of understanding to contribute to the process. Synthetic biology is expected to play an important role in the programme.

GermanyGermany

13.05.2010

Martinsried – SuppreMol GmbH has enrolled the first patient in a Phase Ib/IIa clinical trial with SM101, a treatment for Idiopathic Thrombocytopenic Purpura (ITP). Up to 36 patients will receive 4 weekly doses of the recombinant,...

GermanyGermany

12.05.2010

Life Technologies PD-Direct® has partnered with Cytovance Biologics to demon­strate rapid process transfer and scale-up using new media developed for fed batch processes and DASGIP Bioreactors. The new media were developed by...

GermanyGermany

12.05.2010

Tübingen — German mRNA vaccine specialist CureVac GmbH has secured a 27.6 million euro financing round with Dievini Hopp BioTech Holding. The company has announced that it will use the proceeds to drive forward its programmes for...

GermanyGermany

04.05.2010

Berlin - On Monday, German NOXXON Pharma AG announced the successful completion of a Phase I trial with the 1st "Spiegelmer" NOX-A12, an antagonist of stromal cell-derived factor-1 (SDF-1). Final data analysis demonstrated an...

GermanyGermany

30.04.2010

Berlin/Chicago – Despite the financial crisis, the German biotechnology sector grew in the last year. According to a brand-new biotech-report commissioned by the German Research Ministry and published just a couple of days...

GermanyGermany

19.04.2010

Munster – Germany’s federal state North-Rhine Westfalia is to channel EUR 80million into the medical applications of stem cell research. On Friday, the country’s minister Juergen Ruettgers announced that the money will be used...

GermanyGermany

15.04.2010

Wuppertal – Bayer’s anti-infectives spin-out AiCuris has raised EUR 55 million in this year’s largest financing round of a German biotech company lead by the existing shareholders. The money will be used to push Aicuris clinical...

GermanyGermany

01.04.2010

Berlin - On March 30th, Berlin-based biomarker specialist Epigenomics, successfully raised EUR 33,1 million at the public market through the placement of 14,697,361 new shares. The offering started on March 15 at a subscription...

Displaying results 111 to 120 out of 454

< Previous 111-120 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/11/article/germany-launches-eur200-million-biotechnology-research-programme.html

Image Gallery

Stock list

All quotes

TOP

  • MORPHOSYS (D)62.00 EUR11.8%
  • BIOINVENT INTERNATIONAL AB (S)2.96 SEK10.9%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%

FLOP

  • CYTOS (CH)0.17 CHF-26.1%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • FLAMEL TECHNOLOGIES (F)9.94 USD-9.7%

TOP

  • CO.DON (D)3.30 EUR88.6%
  • BIOTECH PHARMACON (N)17.50 NOK59.1%
  • WILEX (D)0.92 EUR50.8%

FLOP

  • CYTOS (CH)0.17 CHF-94.1%
  • BIONOR PHARMA (N)2.11 NOK-49.0%
  • GW PHARMACEUTICALS (UK)219.25 GBP-39.6%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6143.9%
  • IXICO (UK)71.50 GBP807.4%
  • PLETHORA (UK)10.62 GBP585.2%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.7%
  • AGENNIX (D)0.04 EUR-80.0%

No liability assumed, Date: 16.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper